DNA Script facilitates biological and scientific development through providing proprietary equipment to labs that facilitates in-house DNA synthesis. The equipment eliminates the need for a reliance on external sources, and can significantly speed up workflows and operational efficiencies.

An issue found with equipment is that the DNA synthesised may vary in quality across locations, a problem that the company is committed to addressing through investigations and evaluation. By increasing the ability of labs to carry out DNA synthesis, the possibilities of the tech are vast and have the potential for significant revolutionary scientific developments. 2022 funding has facilitated the advance of DNA Script's SYNTAX Platform, allowing scientists to print synthetic nucleic acids, avoiding the need for third-party waiting times.